ReLiver
®
​
Derived from an unlimited stem cell source, our cell therapy platform will ultimately transform the treatment of liver disease. We are initially targeting acute and acute-on-chronic liver failure, the most challenging conditions that currently rely on liver transplantation as the only line of treatment.
ReLiver® has been designed to be:
-
Used as an allogeneic cell therapy
-
Implantable via minimally invasive surgery
-
Fully functional upon implantation
-
Easily removed without sequelae once the patient’s liver regenerates
-
Does not require immunosuppression
-
Can be cryopreserved for on-demand use
Pre-clinical data supports that ReLiver® :
-
Maintains metabolic function for >18 weeks
-
Restores liver function in representative small and large animal models of acute and acute-on-chronic liver failure, improving survival and treating hepatic encephalopathy
-
Is safe: cells are contained within the implant, the implant is transient and easily removed
-
Effectively evades the host immune system, with no rejection or inflammation